When patients were grouped by KRAS CN and a stratified Cox regression analysis was performed, patients with a CN >7 showed a highly significant, worse clinical outcome (survival) compared with patients with lower CN amplifications ( Fig. 2B and C ).
← all excerpts
Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification.
1
—
—